Adopting a uniform approach to site assignment in Tubo-ovarian high-grade serous carcinoma: The time has come

International Journal of Gynecological Pathology

Volumn 35, Issue 3, 2016, Pages 230-237

  Singh, Naveena ^a   Gilks, C Blake ^e   Hirshowitz, Lynn ^b   Wilkinson, Nafisa ^c   McCluggage, W Glenn ^d  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Fallopian tube; High grade serous carcinoma; Origin; Ovary; Pathology; Primary peritoneal carcinoma; Staging; STIC

Indexed keywords

CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CLONAL VARIATION; DATA COLLECTION METHOD; EVIDENCE BASED PRACTICE; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; MEDICAL TERMINOLOGY; OVARY CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; TISSUE SECTION; TUBAL MUCOSAL INVASIVE CARCINOMA; TUBO OVARIAN HIGH GRADE SEROUS CARCINOMA; TUMOR DIFFERENTIATION; UTERINE TUBE CARCINOMA; CYSTADENOCARCINOMA; FALLOPIAN TUBE; METASTASIS; OVARY TUMOR; PATHOLOGY; UTERINE TUBE TUMOR;

CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HUMANS; NEOPLASM GRADING; NEOPLASM METASTASIS; OVARIAN NEOPLASMS;

EID: 84961231023     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000270     Document Type: Review

References (44)

1. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-6.
2. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5:35-44.
3. Jarboe EA, Folkins AK, Drapkin R, et al. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2008;53:127-38.
4. Singh N, Gilks CB, Wilkinson N, et al. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology. 2014;65:149-54.
5. Singh N, Gilks CB, Wilkinson N, et al. Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology. 2015;67:331-7.
6. McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2015;28:1101-22.
7. Singh N, Gilks CB, Wilkinson N, et al. The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian highgrade serous carcinoma and why assignment of primary site matters. Pathology. 2015;47:423-31.
8. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. WHO Classification of Tumors of the Female Reproductive Organs, 4th Edition. Lyon: International Agency for Research on Cancer, 2014.
9. Tavassoli FA, Devilee P. eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon: International Agency for Research on Cancer (IARC); 2003.
10. Anglesio MS, Bashashati A, Wang YK, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015;236:201-9.
11. Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol. 2011;120:470-3.
12. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004;191:718-32.
13. Lee S, Nelson G, Duan Q, et al. Precursor lesions and prognostic factors in primary peritoneal serous carcinoma. Int J Gynecol Pathol. 2013;32:547-55.
14. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-5.
15. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30:1222-30.
16. George SH, Shaw P. BRCA and early events in the development of serous ovarian cancer. Front Oncol. 2014;(4):1-8.
17. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-6.
18. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407-16.
19. Gross AL, Kurman RJ, Vang R, et al. Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol. 2010;2010:1-9.
20. Seidman JD, Vang R, Ronnett BM, et al. Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22- year series of 562 patients with uniform current histological classification. Gynecol Oncol. 2015;136:336-40.
21. Gilks CB, Irving J, Kobel M, et al. Incidental nonuterine highgrade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Am J Surg Pathol. 2015;39:357-64.
22. Morrison JC, Blanco LZ, Jr, Vang R, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol. 2015;39:442-53.
23. Semmel DR, Folkins AK, Hirsch MS, et al. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009;22:985-8.
24. Rabban JT, Garg K, Crawford B, et al. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014;38:729-42.
25. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49-56.
26. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.
27. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-9.
28. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic highgrade serous carcinoma - evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226:421-6.
29. McDaniel AS, Stall JN, Hovelson DH, et al. Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol. 2015.
30. Rabban JT, Vohra P, Zaloudek CJ. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia. Am J Surg Pathol. 2015;39:35-51.
31. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2010;34:829-36.
32. Bashashati A, Ha G, Tone A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013;231:21-34.
33. Kim YN, Koo KH, Sung JY, et al. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012;2012:1-11.
34. Bijron JG, Seldenrijk CA, Zweemer RP, et al. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37:1123-30.
35. Wethington SL, Park KJ, Soslow RA, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer. 2013;23:1603-11.
36. Conner JR, Meserve E, Pizer E, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingooophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014;132:280-6.
37. Powell CB. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later. Gynecol Oncol. 2014;132:261-3.
38. Carlson JW, Jarboe EA, Kindelberger D, et al. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol. 2010;29:310-4.
39. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol. 2011;35:1766-75.
40. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31:243-53.
41. Singh N, Gilks CB, Huntsman DG, et al. Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. Histopathology. 2014;64:626-32.
42. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol. 2004;23:97-9.
43. Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121:14-24.
44. Gilks CB, Miller D. Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come. Gynecol Oncol. 2013;129:443-4.